Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to treat patients experiencing poorly controlled symptoms, despite standard-of-care (SoC) treatment. Although biological treatment options for AR remain limited worldwide, the recent approval of novel agents, such as stapokibart for seasonal allergic rhinitis (SAR), has accelerated clinical research and development in this field. Evidence for biologic therapy in the management of perennial allergic rhinitis (PAR) is currently sparse. To standardise the use of biologics in AR management and promote their evidence-based application, a multidisciplinary expert panel was convened. This position paper evaluates current evidence regarding the efficacy and safety of biologic agents for AR, incorporating data from both international and regional clinical studies. Here, we provide recommendations on appropriate indications for biologic therapy and emphasise its role in patients with uncontrolled SAR, supporting clinical decision-making and facilitating the integration of biologics into routine practice.

Institutions

Publication Details

Journal
Allergy
Published
2026-03-23
DOI
https://doi.org/10.1111/all.70312
Primary Topic
Allergic Rhinitis and Sensitization
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

Allergy
Allergic Rhinitis and Sensitization
article

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

article en

Abstract

Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to treat patients experiencing poorly controlled symptoms, despite standard-of-care (SoC) treatment. Although biological treatment options for AR remain limited worldwide, the recent approval of novel agents, such as stapokibart for seasonal allergic rhinitis (SAR), has accelerated clinical research and development in this field. Evidence for biologic therapy in the management of perennial allergic rhinitis (PAR) is currently sparse. To standardise the use of biologics in AR management and promote their evidence-based application, a multidisciplinary expert panel was convened. This position paper evaluates current evidence regarding the efficacy and safety of biologic agents for AR, incorporating data from both international and regional clinical studies. Here, we provide recommendations on appropriate indications for biologic therapy and emphasise its role in patients with uncontrolled SAR, supporting clinical decision-making and facilitating the integration of biologics into routine practice.

Allergy
Beijing Tongren Hospital (CN), Fujian Medical University (CN), Union Hospital (HK), Central South University (CN), Nanchang University (CN), Shandong University (CN), Sun Yat-sen University (CN), Shanxi Medical University (CN), Capital Medical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Tianjin First Center Hospital (CN), China-Japan Friendship Hospital (CN), Peking Union Medical College Hospital (CN), Yuhuangding Hospital (CN), Wuhan University (CN), Qinghai University Affiliated Hospital (CN), Yinchuan First People's Hospital (CN), Shanghai Changzheng Hospital (CN), Cangzhou Central Hospital (CN), Second Hospital of Shandong University (CN), Eye & ENT Hospital of Fudan University (CN), The People's Hospital of Guangxi Zhuang Autonomous Region (CN), Shandong Provincial Hospital (CN), Beijing Hospital (CN), Zhongnan Hospital of Wuhan University (CN), First Affiliated Hospital of Fujian Medical University (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), First Hospital of Shanxi Medical University (CN), First Affiliated Hospital of GuangXi Medical University (CN), Baotou Central Hospital (CN), Ningxia Medical University (CN), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Second Affiliated Hospital of Xi'an Jiaotong University (CN), Second Hospital of Shanxi Medical University (CN), Ningxia Medical University General Hospital (CN), Renmin Hospital of Wuhan University (CN), Ministry of Education (TW), Beijing Municipal Education Commission (CN), Guangdong Academy of Medical Sciences (CN), Third Affiliated Hospital of Sun Yat-sen University (CN), Central Hospital of Zibo (CN), Xiangya Hospital Central South University (CN), Qilu Hospital of Shandong University (CN), Union Hospital (CN), First Affiliated Hospital of Nanchang University (CN), Tianjin Medical University (CN), Nanjing Medical University (CN), Chongqing Medical University (CN), China Medical University (CN)
Peace, Justice and strong institutions
Openalex Percentile: Top 8%
Allergic Rhinitis and Sensitization
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.